A preliminary benefit-risk assessment of verteporfin in age-related macular degeneration

Drug Safety : an International Journal of Medical Toxicology and Drug Experience
Jason Wickens, Kevin J Blinder

Abstract

The prevalence of neovascular age-related macular degeneration (AMD) is expected to increase significantly during the next 20 years. New treatment alternatives to laser photocoagulation are on the horizon - the first of these, photodynamic therapy (PDT) with verteporfin, was approved by the US FDA in 2000. In this article we present a preliminary risk-benefit assessment of verteporfin in AMD, focusing on the landmark randomised, double-blind, placebo-controlled studies. The TAP (Treatment of Age-related macular degeneration with Photodynamic therapy) trial established the efficacy of PDT for classic subfoveal neovascularisation in AMD at 2 years follow-up. The VIP (Verteporfin in Photodynamic therapy) study concentrated on subfoveal occult-only lesions not included in the TAP study. After 2 years, treated eyes were less likely to experience visual loss. Exploratory analyses of TAP and VIP suggest that lesion size is a more significant predictor of the treatment benefit than either lesion composition or visual activity. The VIM (Visudyne in Minimally classic) trial altered the standard PDT light fluence rate in the treatment of subfoveal minimally classic lesions. This trial again demonstrated a beneficial effect for those recei...Continue Reading

References

May 1, 1988·Survey of Ophthalmology·N M BresslerS L Fine
May 11, 1989·La Revue du praticien·G Soubrane, G Coscas
Nov 1, 1984·Archives of Ophthalmology·F L FerrisL Hyman
Jan 1, 1993·Graefe's Archive for Clinical and Experimental Ophthalmology = Albrecht Von Graefes Archiv Für Klinische Und Experimentelle Ophthalmologie·A N AntoszykD L Hatchell
Apr 8, 2000·Drugs & Aging·L J Scott, K L Goa
May 23, 2002·Journal of Clinical Pharmacology·Jean-Marie Houle, Andrew Strong
Oct 17, 2002·Archives of Ophthalmology·Mark S BlumenkranzUNKNOWN Treatment of Age-Related Macular Degeneration with Photodynamic Therapy (TAP) Study Group
Nov 21, 2002·Retina·Gary S RubinUNKNOWN Treatment of Age-Related Macular Degeneration with Photodynamic therapy (TAP) study group
Jan 18, 2003·Archives of Ophthalmology·Neil M Bressler
Sep 26, 2003·Investigative Ophthalmology & Visual Science·Ursula Schmidt-ErfurthGottfried O H Naumann
Apr 3, 2004·American Journal of Ophthalmology·Jennifer J ArnoldUNKNOWN Verteporfin in Photodynamic Therapy Study Group
Nov 4, 2004·Ophthalmology·Barbara S HawkinsUNKNOWN Submacular Surgery Trials (SST) Research Group
Dec 31, 2004·The New England Journal of Medicine·Evangelos S GragoudasUNKNOWN VEGF Inhibition Study in Ocular Neovascularization Clinical Trial Group
Apr 13, 2005·Archives of Ophthalmology·Mohammad AzabUNKNOWN Visudyne in Minimally Classic Choroidal Neovascularization Study Group

❮ Previous
Next ❯

Citations

Jun 15, 2007·Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft·R HahnU Schmidt-Erfurth
Jan 2, 2008·Journal of the American Chemical Society·William G O'Neal, Peter A Jacobi
Nov 28, 2006·Dermatologic Clinics·Amy Forman Taub
Sep 15, 2011·Molecular Diagnosis & Therapy·Francesco ParmeggianiCarlo Incorvaia
Jun 24, 2009·Deutsches Ärzteblatt International·Antonia M Joussen, Norbert Bornfeld

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.